



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

10/657,298 09/08/2003 William E. Jack NEB-180-DIV 9741 28986 7590 03/16/2006 EXAMINER HARRIET M. STRIMPEL; NEW ENGLAND BIOLABS, INC. 240 COUNTY ROAD	APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKE	ET NO. CONFIRMATION N	10.
HARRIET M. STRIMPEL; NEW ENGLAND BIOLABS, INC. 240 COUNTY ROAD	10/657,298		09/08/2003	William E. Jack	NEB-180-DIV	9741	
240 COUNTY ROAD	28986	7590	03/16/2006			EXAMINER	
	HARRIET	M. STRI	MPEL; NEW ENC	LU, FRANK WEI MIN			
	240 COUNT	Y ROAD			ART UNIT	PAPER NUMBER	
					1634		

DATE MAILED: 03/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
		10/657,298	JACK ET AL.	
	Office Action Summary	Examiner	Art Unit	
		Frank W. Lu	1634	
Period fo	The MAILING DATE of this communication or Reply	appears on the cover sheet	with the correspondence a	ddress
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING assions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication of period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	B DATE OF THIS COMMURA 1.136(a). In no event, however, may riod will apply and will expire SIX (6) Matute, cause the application to become	NICATION. y a reply be timely filed MONTHS from the mailing date of this of a BANDONED (35 U.S.C. § 133).	
Status				
1)[]	Responsive to communication(s) filed on _			
·	· · · · · · · · · · · · · · · · · · ·	This action is non-final.		
3)[Since this application is in condition for allo	wance except for formal m	atters, prosecution as to th	e merits is
	closed in accordance with the practice under	er <i>Ex parte Quayle</i> , 1935 (C.D. 11, 453 O.G. 213.	
Dispositi	on of Claims			
4)⊠	Claim(s) 22-29 is/are pending in the applica	ation.		
	4a) Of the above claim(s) is/are with	drawn from consideration.		
5)	Claim(s) is/are allowed.			
6)□	Claim(s) is/are rejected.			
7)	Claim(s) is/are objected to.			
8)⊠	Claim(s) 22-29 are subject to restriction and	d/or election requirement.		
Applicati	on Papers		·	
9)□	The specification is objected to by the Exam	niner.		
10)	The drawing(s) filed on is/are: a)	accepted or b) objected	to by the Examiner.	
	Applicant may not request that any objection to	the drawing(s) be held in abe	yance. See 37 CFR 1.85(a).	
	Replacement drawing sheet(s) including the cor	rection is required if the draw	ing(s) is objected to. See 37 C	FR 1.121(d).
11)	The oath or declaration is objected to by the	Examiner. Note the attacl	ned Office Action or form P	TO-152.
Priority u	ınder 35 U.S.C. § 119			
	Acknowledgment is made of a claim for fore ☐ All b) ☐ Some * c) ☐ None of:	eign priority under 35 U.S.C). § 119(a)-(d) or (f).	~
u) _i	1. ☐ Certified copies of the priority docum	ents have been received		
	Certified copies of the priority docum		n Application No.	
	3. Copies of the certified copies of the p		· ·	I Stage
	application from the International Bur	*		
* 5	See the attached detailed Office action for a	list of the certified copies r	ot received.	
Attachmen				
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)		ew Summary (PTO-413) No(s)/Mail Date	
3) 🔲 Infor	e of Dransperson's Patent Drawing Review (P10-948) nation Disclosure Statement(s) (PT0-1449 or PTO/SB r No(s)/Mail Date	/08) 5) ∐ Notice ⋅	of Informal Patent Application (PT Notice for sequencing listing.	O-152)

Application/Control Number: 10/657,298 Page 2

Art Unit: 1634

DETAILED ACTION

Election/Restrictions

Sequence Election Requirement Applicable to claims 28 and 29 of this instant application
 Claims 28 and 29 read on patentably distinct SEQ ID Numbers. Each sequence in claims
 28 and 29 is patentably distinct because these sequences are structurally unrelated sequences.
 Therefore, applicant must elect a single SEQ ID NO. (See MPEP 803.04). Applicant is advised that examination will be restricted to only elected SEQ ID NO. and should not to be construed as a species election.

Sequence Rules Compliance

2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). Since this instant application does not have paper copy of the sequencing listing, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Direct the reply to the undersigned.

3. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30

Application/Control Number: 10/657,298 Page 3

Art Unit: 1634

(November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571)272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Frank Lu Primary Examiner March 15, 2006

FRANK LU
PRIMARY EXAMINER

Julian

Application No.: 10/617,298

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 111 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ар	plicant Must Provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or
	1.825(b) or 1.825(d).
For For	1.825(b) or 1.825(d).

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY